Sichuan Huiyu Pharmaceutical Co Ltd (688553) Fair Value & Analysis
Healthcare · CN · Market cap 7.7B CNY
Risks
Fair value as of: Aug 21, 2026
From 4 valuation models · updated 5 days ago
Share price +18.9% over the past month.
A solid business, but trading 254% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥3.53). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
- The models converge in a tight band (¥3.23 to ¥3.53), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 21, 2026.
How to read this chart
58‑month range ¥6.30 – ¥24.60 · fair‑value band ¥3.23 – ¥3.53 · the ¥11.96 price screens above the ¥3.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 21, 2026.
Analysis
Sichuan Huiyu Pharmaceutical Co Ltd (688553) currently trades at ¥11.96, while our model-based Fair Value estimate is ¥3.38, implying the stock looks roughly 71.7% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Sichuan Huiyu Pharmaceutical Co Ltd generated revenue of 1.0B CNY at a net margin of 2.2%. Revenue grew 12.6% year over year. It earns a return on equity of 0.5%. The balance sheet holds a net cash position of 1.7B CNY. Fundamentals as of Aug 21, 2026
Our scenario range runs from ¥3.23 (bear case) to ¥3.53 (bull case); at ¥11.96, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -35% fair-value upside, at -72%, 688553 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 4 models by family
Widest divergence: Dividend Discount (¥4.81) versus Asset-Based (¥4.02). Highest evidence: Gordon GGM (70).
Notify me when 688553 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 32
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally.
Full company description
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. It also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, panosetron hydrochloride, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, thiotepa, teicoplanin, epirubicin hydrochloride, methotrexate, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine acetate hydrochloride, and bortezomib drugs. Sichuan Huiyu Pharmaceutical Co., Ltd. was incorportaed in 2010 and is headquartered in Neijiang, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sichuan Huiyu Pharmaceutical Co Ltd reported revenue of ¥998M in FY2025 versus ¥1.8B in FY2021, a compound −14.0%/yr. Reported net income was −¥24.2M in FY2025.
688553 screens 72% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 633 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.00 | €106.48 | -24% |
| Takeda Pharmaceutical Company TAK | $17.41 | $11.29 | -35% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | -69% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Haleon plc HLN | $9.80 | $7.62 | -22% |
| Teva Pharmaceutical Industries Limited TEVA | $36.74 | $15.37 | -58% |
| Sandoz Group SDZ | CHF 72.64 | CHF 48.68 | -33% |
| Zoetis Inc ZTS | $73.54 | $104.88 | +43% |
| Hansoh Pharmaceutical Group 3692 | HK$33.50 | HK$16.14 | -52% |
Compare Sichuan Huiyu Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Sichuan Huiyu Pharmaceutical Co Ltd (688553) overvalued or undervalued?
What is the fair value of 688553?
What is the quality score of 688553?
What is the revenue of Sichuan Huiyu Pharmaceutical Co Ltd (688553)?
What is the net profit margin of 688553?
Does Sichuan Huiyu Pharmaceutical Co Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sichuan Huiyu Pharmaceutical Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.